Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute myeloid leukaemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    406 result(s) found for: Acute myeloid leukaemia. Displaying page 21 of 21.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    EudraCT Number: 2013-000903-18 Sponsor Protocol Number: 0113-CL-1004 Start Date*: 2013-06-19
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Unde...
    Medical condition: CMV reactivation after allogeneic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10049107 CMV viraemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001141-80 Sponsor Protocol Number: POLA/ACOG1401 Start Date*: 2015-07-27
    Sponsor Name:Andrés Poveda
    Full Title: Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors
    Medical condition: Advanced or metastatic solid tumors (Phase I) Patients with potential tumors with possibly sensitivity to PARP inhibitors according to histology, or patients with molecular features (Phase II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004384-39 Sponsor Protocol Number: ABCSG-45 Start Date*: 2018-12-18
    Sponsor Name:Austrian Breast & Colorectal Cancer Study Group (ABCSG)
    Full Title: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive ...
    Medical condition: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003422-32 Sponsor Protocol Number: AMoRe2017 Start Date*: 2018-04-25
    Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) gGmbH
    Full Title: INTERNATIONAL MULTICENTER, OPEN-LABEL, PHASE 2 STUDY TO TREAT MOLECULAR RELAPSE OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH AZACITIDINE
    Medical condition: Intravenous azacitidine 100 mg/m2, Days 1 to 7 of a 28-day cycle for up to 3 cycles initially. In case of decline of MRD during azacitidine treatment additional cycles are allowed (maximum 6 cycl...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Prematurely Ended) SE (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000104-15 Sponsor Protocol Number: CCS1477-02 Start Date*: 2021-07-29
    Sponsor Name:CellCentric Ltd
    Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.
    Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003576-40 Sponsor Protocol Number: 74494550MDS2001 Start Date*: 2020-04-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomo...
    Medical condition: Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054350 Chronic myelomonocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 23:26:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA